This post uses hypothetical scenarios for illustrative purposes only. It does not describe any actual client, transaction, or representation, and is not legal advice.
A common Florida deal pattern looks like this: a private equity group with two behavioral health platforms in other states signs a letter of intent to buy a Florida addiction treatment company — a detox facility, two residential programs, and an outpatient location, all licensed, all accredited, census strong. The model assumes a sixty-day close. Then the regulatory memo comes back and the sixty days quietly becomes five months, because the target’s most important asset — its license — is the one thing on the balance sheet the seller cannot hand over. And the second-most important diligence question turns out to be criminal law, not health law.
The Chapter 397 license does not transfer — and 2026 changed what “transfer” means
Substance abuse service providers in Florida are licensed by the Department of Children and Families under chapter 397, Florida Statutes. The license is issued to a specific legal entity, for specific service components — detoxification, residential treatment, day or night treatment, outpatient, and so on — at specific locations. Section 397.407 says flatly that a license may not be transferred. And the statute defines “transfer” to reach the deal itself, not just an assignment of the paper: a transfer includes moving a majority of the ownership interest in the licensed entity, or handing the responsibilities under the license to another entity by contract. A stock or membership-interest sale that flips majority ownership is a transfer. A management agreement that shifts operational responsibility can be a transfer. The buyer does not inherit the license; the buyer applies for one.
The 2026 Legislature sharpened this framework in CS/CS/SB 1030, effective July 1, 2026. The amendments narrowed the “transfer” definition to those two triggers — majority ownership changes and contractual handoffs of license responsibility — and recalibrated the background-screening machinery that rides along with ownership changes: when five percent or more of the controlling ownership interest in a licensed entity moves, level 2 background screening applies to the officers, directors, managing members, and individuals who exercise operational control. Read those two rules together and the practical picture for deal planning is clear. Minority tuck-in investments below majority control sit outside the relicensure trigger, but they can still fire the screening requirement. And any control deal — however structured — puts DCF between signing and closing.
That has three consequences for the timeline. First, the application work starts at the letter of intent, not at signing. The buyer’s entity, its principals, its screening file, and its policies all go into the licensure process, and DCF’s probationary and interim licensure categories exist precisely to bridge operators through transitions — but bridges have to be built before you drive onto them. Second, the purchase agreement should treat licensure the way it treats antitrust clearance in a bigger deal: a closing condition with a drop-dead date, cooperation covenants running both directions, and an operating covenant that keeps the seller’s license in good standing and its census stable in the interim. Third, the structure conversation changes. Florida deal lawyers reflexively reach for asset deals in licensed industries, but here even the stock deal walks through the licensure door at majority change — so the structure choice runs on tax and liability logic, the way it does in the neighboring world of AHCA change-of-ownership deals, while the licensure timeline stays roughly constant either way.
The Patient Brokering Act is the diligence spine
Now the criminal statute. Florida’s Patient Brokering Act, section 817.505, makes it a felony to offer, pay, solicit, or receive any commission, bonus, rebate, kickback, or bribe — directly or indirectly, in cash or in kind — to induce the referral of patients to or from a health care provider or facility, or to engage in any split-fee arrangement. Aiding and abetting is its own violation. The penalties scale with patient count: a base violation is a third-degree felony with a mandatory $50,000 fine, prohibited conduct involving ten or more patients is a second-degree felony with a $100,000 fine, and twenty or more patients makes it a first-degree felony with a $500,000 fine. The statute reaches corporate and individual defendants — officers, partners, agents, and attorneys are named in the text.
Two features make this statute the center of gravity in treatment-industry diligence. It is payor-blind: unlike the federal Anti-Kickback Statute, which is tied to federal health care programs, the Patient Brokering Act applies to cash-pay and commercial-insurance patients — which describes most of the Florida addiction treatment economy. And its safe harbors are borrowed: the statute excepts payment practices not prohibited by 42 U.S.C. § 1320a-7b(b) and its regulations, which means a marketing arrangement generally needs to fit a federal safe-harbor concept — fair market value, not volume-based — even in an all-commercial business. Employment relationships and group-practice compensation have room to operate; per-admission bonuses to marketers generally do not. Federal law layers its own analog on top for this industry: the Eliminating Kickbacks in Recovery Act reaches recovery homes, clinical treatment facilities, and laboratories regardless of payor. A compensation structure that fails these tests is not a contract problem. It is a felony pattern with a per-patient multiplier.
So the diligence list for a Florida treatment platform starts where the patients come from. Pull every marketing and business-development agreement, every call-center and lead-generation contract, and the compensation plans for anyone whose job touches admissions — and read how the people who fill beds are actually paid. Percentage-of-collections deals, per-head bonuses, and “consulting” arrangements with sober homes that feed referrals are the classic patterns. Look at the relationship map around housing: payments between treatment providers and recovery residences, free rent, scholarships tied to enrollment. Look at laboratory economics, because urine drug testing volume has historically been where the money hid. And read the marketing itself against section 397.55’s prohibition on deceptive marketing practices — the statute chapter 397 aims at call aggregators and misleading admissions funnels. None of this is exotic; it is the same fee-splitting logic Florida applies to physician practice deals under section 458.331, with prison attached.
Pricing the risk into the papers
What does the purchase agreement do with all this? First, the representations get specific. A generic healthcare-compliance rep is not enough; the buyer wants the seller standing behind statements that no owner, employee, or contractor has paid or received remuneration for referrals, that marketing arrangements comply with section 817.505 and the federal statutes it incorporates, and that there are no inquiries from the Attorney General, a state attorney, or DCF. Second, the indemnity architecture should treat referral-practice exposure as a specified indemnity outside the general cap and basket if diligence surfaced anything gray — pre-closing conduct stays with the people who profited from it, and an escrow sized to the realistic exposure beats a lawsuit against distributed proceeds. Third, interim covenants should freeze the marketing stack: no new lead-gen contracts, no comp-plan changes for admissions staff, between signing and closing. Fourth, remember the payors and accreditors have their own change-of-ownership machinery — Medicaid enrollment, managed-care contracts, and Joint Commission or CARF accreditation all need notices or applications on their own clocks, and the licensure condition should not be the only regulatory gate in the closing conditions.
The treatment industry earns its scrutiny, and the sellers who run clean shops earn their premiums. A Florida platform that can show W-2 admissions staff on salary, marketing contracts at fair market value, arm’s-length housing relationships, and a quiet regulatory file is a fundamentally more valuable business than one with a brilliant census and an unexplainable marketing line item — because the first one can be bought, licensed, and financed on schedule, and the second one is asking the buyer to purchase a felony multiplier. The deal process is where that difference gets priced.
If you are buying or selling a licensed treatment provider in Florida, feel free to reach out to my firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
